LEADER 01519nam  2200433   450 
001 9910707255103321
005 20160614085340.0
035   $a(CKB)5470000002462957
035   $a(OCoLC)951671986
035   $a(OCoLC)995470000002462957
035   $a(EXLCZ)995470000002462957
100   $a20160614d2013      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aGaps in oversight of conflicts of interest in Medicare prescription drug decisions
210  1$a[Washington, D.C.] :$cDepartment of Health and Human Services, Office of Inspector General,$d2013.
215   $a1 online resource (32 pages) $ccolor illustrations
300   $aTitle from title screen (viewed June 13, 2016).
300   $a"March 2013."
300   $a"OEI-05-10-00450."
320   $aIncludes bibliographical references.
517 1 $aGaps in oversight of conflicts of interest in Medicare prescription drug decisions
606   $aMedicare
606   $aConflict of interests$zUnited States
606   $aDrugs$zUnited States
606   $aPharmaceutical services$zUnited States$xEthics
615  0$aMedicare.
615  0$aConflict of interests
615  0$aDrugs
615  0$aPharmaceutical services$xEthics.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910707255103321
996   $aGaps in oversight of conflicts of interest in Medicare prescription drug decisions$93348153
997   $aUNINA